GeneDx (NasdaqGS:WGS) 2025 Conference November 19, 2025 06:00 AM ET Speaker1Okay, we're going to kick it off. I'm Tucker Peterson from the Life Science Team. It's my pleasure to introduce our next company, GeneDx. With us, we have Katherine and Kevin. Welcome to you both. You've had a great year. You've beaten rays each quarter, a number of new indications, multiple newborn screening partnerships, breakthrough device approval, got the guideline update. Maybe just talk a little bit about some of the momentum ...

Core Viewpoint - The article discusses the complexities and limitations of cancer screening, emphasizing that not all screening methods are effective and that many can lead to false positives and false negatives [1][2][3]. Group 1: Limitations of Current Screening Methods - Effective cancer screening should improve survival rates, but many existing methods do not meet this standard [2][4]. - False negatives (missed tumors) and false positives (incorrectly identified tumors) are significant issues in cancer screening, leading to unnecessary anxiety and financial burden [7][8]. - Many commonly used tumor markers are not recommended for healthy individuals due to high rates of false results [7][10]. Group 2: Recommended Screening Methods - Recommended screening methods include colonoscopy for colorectal cancer, gastroscopy for gastric cancer, low-dose spiral CT for high-risk lung cancer, mammography and ultrasound for breast cancer, and cytology and HPV testing for cervical cancer [8][11]. - The age at which screening should begin varies by cancer type, with guidelines suggesting starting at 45 for colorectal cancer and 40 for breast cancer [11][12]. Group 3: Future Directions in Cancer Screening - There is ongoing research into new screening methods, including liquid biopsies that detect cancer-related DNA in blood and the use of artificial intelligence for early tumor detection through imaging [12][13].